Symbols / CNTA Stock $39.48 +0.05% Centessa Pharmaceuticals plc

Healthcare • Biotechnology • United Kingdom • NMS
CNTA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Mario Alberto Accardi Ph.D.
Exch · Country NMS · United Kingdom
Market Cap 6.11B
Enterprise Value 5.92B
Income -197.53M
Sales 15.00M
FCF (ttm) -138.54M
Book/sh 3.53
Cash/sh 1.91
Employees 118
Insider 10d —
IPO May 28, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -20.82
PEG —
P/S 407.07
P/B 11.18
P/C —
EV/EBITDA -28.56
EV/Sales 394.87
Quick Ratio 8.27
Current Ratio 8.57
Debt/Eq 22.47
LT Debt/Eq —
EPS (ttm) -1.46
EPS next Y -1.90
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-03-31
ROA -20.53%
ROE -42.55%
ROIC —
Gross Margin 100.00%
Oper. Margin -13.85%
Profit Margin 0.00%
Shs Outstand 154.66M
Shs Float 97.86M
Insider Own 0.47%
Instit Own 98.04%
Short Float 2.58%
Short Ratio 0.73
Short Interest 3.47M
52W High 40.26
vs 52W High -1.94%
52W Low 10.95
vs 52W Low 260.55%
Beta 1.26
Impl. Vol. 16.41%
Rel Volume 0.18
Avg Volume 2.63M
Volume 482.35K
Target (mean) $44.57
Tgt Median $42.00
Tgt Low $38.00
Tgt High $62.00
# Analysts 7
Recom Buy
Prev Close $39.46
Price $39.48
Change 0.05%
About

Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$44.57
Mean price target
2. Current target
$39.48
Latest analyst target
3. DCF / Fair value
$-16.12
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$39.48
Low
$38.00
High
$62.00
Mean
$44.57

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-20 down Wells Fargo Overweight → Equal-Weight $42
2026-04-02 down Guggenheim Buy → Neutral —
2026-04-01 down Leerink Partners Outperform → Market Perform $40
2026-03-31 down Wolfe Research Outperform → Peer Perform —
2026-03-31 down Needham Buy → Hold —
2026-02-24 init Wolfe Research — → Outperform $40
2026-01-29 main Truist Securities Buy → Buy $38
2026-01-08 main Truist Securities Buy → Buy $33
2026-01-02 main Chardan Capital Buy → Buy $30
2026-01-02 main Chardan Capital Buy → Buy $30
2025-12-10 main Oppenheimer Outperform → Outperform $62
2025-12-01 main B. Riley Securities Buy → Buy $42
2025-11-18 main Guggenheim Buy → Buy $43
2025-11-13 main Wells Fargo Overweight → Overweight $35
2025-11-07 main Wells Fargo Overweight → Overweight $30
2025-10-28 init Stephens & Co. — → Overweight $35
2025-10-06 reit Guggenheim Buy → Buy $28
2025-09-03 init Wells Fargo — → Overweight $31
2025-08-12 main Chardan Capital Buy → Buy $30
2025-07-30 main Chardan Capital Buy → Buy $30
News
RSS: Latest CNTA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-26 WEINHOFF GREGORY M Officer — 23,998 $30.00 $719,940
2026-03-26 WEINHOFF GREGORY M Officer — 23,998 $3.85 $92,392
2026-03-26 ANDERSON KAREN M Officer — 41,076 $30.12 $1,237,382
2026-03-26 ANDERSON KAREN M Officer — 41,076 $8.01 $329,019
2026-03-17 ANDERSON KAREN M Officer — 74,811 $28.10 $2,109,180
2026-03-17 ANDERSON KAREN M Officer — 74,811 $4.01 $299,992
2026-03-13 WEINHOFF GREGORY M Officer — 73,196 $26.17 $1,927,131
2026-03-13 ANDERSON KAREN M Officer — 120,029 $26.15 $3,150,673
2026-03-13 ANDERSON KAREN M Officer — 109,398 $4.01 $438,686
2026-03-13 ANDERSON KAREN M Officer — 120,029 $26.15 $3,150,673
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
15.00
0.00
-100.00%
6.85
0.00
Operating Revenue
15.00
0.00
-100.00%
6.85
0.00
Operating Expense
222.69
+10.76%
201.06
+12.87%
178.14
-15.29%
210.28
Research And Development
172.22
+14.63%
150.24
+20.77%
124.41
-19.78%
155.08
Selling General And Administration
50.47
-0.68%
50.81
-5.43%
53.73
-2.66%
55.20
General And Administrative Expense
50.47
-0.68%
50.81
-5.43%
53.73
-2.66%
55.20
Salaries And Wages
29.39
-4.89%
30.90
+11.84%
27.62
+6.57%
25.92
Other Gand A
21.08
+5.87%
19.91
-23.72%
26.11
-10.84%
29.28
Total Expenses
222.69
+10.76%
201.06
+12.87%
178.14
-15.29%
210.28
Operating Income
-207.69
-3.30%
-201.06
-17.38%
-171.28
+18.55%
-210.28
Total Operating Income As Reported
-207.69
-3.30%
-201.06
-17.38%
-171.28
+19.31%
-212.26
EBITDA
-183.33
+17.37%
-221.88
-34.13%
-165.43
+21.06%
-209.55
Normalized EBITDA
-183.33
+2.37%
-187.78
-13.52%
-165.43
+20.30%
-207.57
Reconciled Depreciation
0.92
-2.23%
0.94
+16.30%
0.81
+518.32%
0.13
EBIT
-184.25
+17.31%
-222.82
-34.04%
-166.24
+20.72%
-209.68
Total Unusual Items
0.00
+100.00%
-34.10
0.00
+100.00%
-1.98
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-34.10
0.00
+100.00%
-1.98
Special Income Charges
0.00
+100.00%
-34.10
0.00
+100.00%
-1.98
Other Special Charges
—
34.10
—
—
Restructuring And Mergern Acquisition
—
—
0.00
-100.00%
1.98
Net Income
-197.53
+16.21%
-235.76
-56.04%
-151.09
+30.12%
-216.21
Pretax Income
-195.71
+15.97%
-232.91
-32.23%
-176.14
+18.81%
-216.95
Net Non Operating Interest Income Expense
9.07
+130.97%
3.93
+588.77%
0.57
+108.10%
-7.03
Interest Expense Non Operating
11.46
+13.57%
10.09
+1.86%
9.91
+36.13%
7.28
Net Interest Income
9.07
+130.97%
3.93
+588.77%
0.57
+108.10%
-7.03
Interest Expense
11.46
+13.57%
10.09
+1.86%
9.91
+36.13%
7.28
Interest Income Non Operating
20.53
+46.45%
14.02
+33.79%
10.48
+4193.44%
0.24
Interest Income
20.53
+46.45%
14.02
+33.79%
10.48
+4193.44%
0.24
Other Income Expense
2.91
+108.13%
-35.78
-559.25%
-5.43
-1599.45%
0.36
Other Non Operating Income Expenses
2.91
+272.55%
-1.69
+68.92%
-5.43
-331.77%
2.34
Tax Provision
1.82
-36.04%
2.84
+111.35%
-25.06
-3254.22%
-0.75
Tax Rate For Calcs
0.00
+0.00%
0.00
+78.57%
0.00
+3966.22%
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-8.52
0.00
+100.00%
-0.01
Net Income Including Noncontrolling Interests
-197.53
+16.21%
-235.76
-56.04%
-151.09
+30.12%
-216.21
Net Income From Continuing Operation Net Minority Interest
-197.53
+16.21%
-235.76
-56.04%
-151.09
+30.12%
-216.21
Net Income From Continuing And Discontinued Operation
-197.53
+16.21%
-235.76
-56.04%
-151.09
+30.12%
-216.21
Net Income Continuous Operations
-197.53
+16.21%
-235.76
-56.04%
-151.09
+30.12%
-216.21
Normalized Income
-197.53
+6.02%
-210.18
-39.12%
-151.09
+29.48%
-214.23
Net Income Common Stockholders
-197.53
+16.21%
-235.76
-56.04%
-151.09
+30.12%
-216.21
Diluted EPS
—
-2.06
-31.21%
-1.57
+32.03%
-2.31
Basic EPS
—
-2.06
-31.21%
-1.57
+32.03%
-2.31
Basic Average Shares
—
114.47
+19.02%
96.18
+2.97%
93.40
Diluted Average Shares
—
114.47
+19.02%
96.18
+2.97%
93.40
Diluted NI Availto Com Stockholders
-197.53
+16.21%
-235.76
-56.04%
-151.09
+30.12%
-216.21
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
687.50
+19.19%
576.80
+60.11%
360.25
-18.92%
444.31
Current Assets
367.88
-31.42%
536.41
+70.24%
315.09
-28.02%
437.75
Cash Cash Equivalents And Short Term Investments
294.58
-38.91%
482.18
+87.95%
256.55
-34.83%
393.64
Cash And Cash Equivalents
61.30
-84.00%
383.22
+199.32%
128.03
-67.48%
393.64
Other Short Term Investments
233.28
+135.74%
98.96
-23.00%
128.52
0.00
Receivables
60.34
+32.38%
45.58
+16.44%
39.15
+46.50%
26.72
Taxes Receivable
56.98
+25.80%
45.30
+15.70%
39.15
+46.50%
26.72
Accrued Interest Receivable
3.36
+1070.73%
0.29
—
—
Prepaid Assets
11.13
+55.54%
7.15
-59.75%
17.77
+25.98%
14.11
Other Current Assets
1.83
+22.21%
1.50
-7.77%
1.62
-50.44%
3.27
Total Non Current Assets
319.62
+691.35%
40.39
-10.55%
45.15
+588.32%
6.56
Net PPE
10.85
-7.68%
11.76
-9.23%
12.95
+1008.99%
1.17
Gross PPE
11.95
-4.74%
12.55
-6.46%
13.41
+907.13%
1.33
Accumulated Depreciation
-1.10
-38.94%
-0.79
-71.21%
-0.46
-181.71%
-0.16
Properties
0.00
0.00
0.00
—
Buildings And Improvements
10.05
-8.77%
11.01
-7.56%
11.91
—
Machinery Furniture Equipment
1.91
+24.17%
1.53
+2.27%
1.50
+239.59%
0.44
Construction In Progress
—
—
0.00
-100.00%
0.89
Investments And Advances
282.55
0.00
—
—
Non Current Deferred Assets
24.78
-6.80%
26.59
-10.32%
29.65
+744.16%
3.51
Non Current Deferred Taxes Assets
24.78
-6.80%
26.59
-10.32%
29.65
+744.16%
3.51
Other Non Current Assets
1.44
-29.62%
2.05
-19.89%
2.55
+35.85%
1.88
Total Liabilities Net Minority Interest
160.63
-8.34%
175.25
+41.33%
124.00
+14.67%
108.14
Current Liabilities
42.94
-25.97%
58.00
+47.26%
39.38
+2.73%
38.34
Payables And Accrued Expenses
27.54
-42.42%
47.82
+50.33%
31.81
+4.70%
30.38
Payables
7.58
-4.96%
7.98
-33.11%
11.93
-22.64%
15.42
Accounts Payable
7.58
+6.15%
7.14
-39.54%
11.81
-14.61%
13.84
Current Accrued Expenses
19.96
-49.92%
39.84
+100.37%
19.89
+32.87%
14.97
Pensionand Other Post Retirement Benefit Plans Current
14.47
+52.85%
9.46
+40.58%
6.73
-7.31%
7.26
Total Tax Payable
0.00
-100.00%
0.83
+645.54%
0.11
-92.92%
1.58
Income Tax Payable
0.00
-100.00%
0.83
+645.54%
0.11
-92.92%
1.58
Current Debt And Capital Lease Obligation
0.71
+18.44%
0.60
—
—
Current Capital Lease Obligation
0.71
+18.44%
0.60
—
—
Other Current Liabilities
0.22
+100.93%
0.11
-87.13%
0.84
+21.59%
0.69
Total Non Current Liabilities Net Minority Interest
117.70
+0.38%
117.25
+38.57%
84.62
+21.23%
69.80
Long Term Debt And Capital Lease Obligation
117.67
+0.38%
117.23
+38.58%
84.59
+21.19%
69.80
Long Term Debt
110.09
+1.06%
108.94
+43.91%
75.70
+8.45%
69.80
Long Term Capital Lease Obligation
7.57
-8.60%
8.29
-6.77%
8.89
0.00
Other Non Current Liabilities
0.03
+0.00%
0.03
+0.00%
0.03
—
Preferred Securities Outside Stock Equity
—
—
—
—
Stockholders Equity
526.86
+31.21%
401.55
+69.97%
236.24
-29.72%
336.17
Common Stock Equity
526.86
+31.21%
401.55
+69.97%
236.24
-29.72%
336.17
Capital Stock
0.41
+12.81%
0.36
+31.50%
0.27
+3.02%
0.27
Common Stock
0.41
+12.81%
0.36
+31.50%
0.27
+3.02%
0.27
Preferred Stock
—
—
—
—
Share Issued
149.23
+12.51%
132.63
+34.28%
98.77
+4.15%
94.84
Ordinary Shares Number
149.23
+12.51%
132.63
+34.28%
98.77
+4.15%
94.84
Additional Paid In Capital
1,709.98
+23.40%
1,385.67
+40.33%
987.42
+5.13%
939.26
Retained Earnings
-1,186.23
-19.98%
-988.70
-31.31%
-752.95
-25.10%
-601.86
Gains Losses Not Affecting Retained Earnings
2.71
-35.58%
4.21
+182.18%
1.49
+199.73%
-1.50
Other Equity Adjustments
2.71
-35.58%
4.21
+182.18%
1.49
+199.73%
-1.50
Total Equity Gross Minority Interest
526.86
+31.21%
401.55
+69.97%
236.24
-29.72%
336.17
Total Capitalization
636.96
+24.78%
510.49
+63.65%
311.94
-23.16%
405.97
Working Capital
324.94
-32.08%
478.41
+73.52%
275.71
-30.97%
399.41
Invested Capital
636.96
+24.78%
510.49
+63.65%
311.94
-23.16%
405.97
Total Debt
118.38
+0.47%
117.83
+39.30%
84.59
+21.19%
69.80
Net Debt
48.80
—
—
—
Capital Lease Obligations
8.29
-6.77%
8.89
+0.00%
8.89
0.00
Net Tangible Assets
526.86
+31.21%
401.55
+69.97%
236.24
-29.72%
336.17
Tangible Book Value
526.86
+31.21%
401.55
+69.97%
236.24
-29.72%
336.17
Derivative Product Liabilities
—
—
—
—
Interest Payable
0.84
0.00
—
—
Line Of Credit
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-193.82
-36.44%
-142.06
+11.40%
-160.34
+20.05%
-200.55
Cash Flow From Continuing Operating Activities
-193.82
-36.44%
-142.06
+11.40%
-160.34
+20.05%
-200.55
Net Income From Continuing Operations
-197.53
+16.21%
-235.76
-56.04%
-151.09
+30.12%
-216.21
Depreciation Amortization Depletion
0.92
-2.23%
0.94
+16.30%
0.81
+518.32%
0.13
Depreciation And Amortization
0.92
-2.23%
0.94
+16.30%
0.81
+518.32%
0.13
Other Non Cash Items
1.15
+1750.00%
0.06
+121.43%
0.03
-83.82%
0.17
Stock Based Compensation
30.96
-7.70%
33.55
+14.13%
29.39
+17.73%
24.96
Deferred Tax
2.51
-5.43%
2.65
+110.00%
-26.53
-828.56%
-2.86
Deferred Income Tax
2.51
-5.43%
2.65
+110.00%
-26.53
-828.56%
-2.86
Operating Gains Losses
—
34.10
—
—
Unrealized Gain Loss On Investment Securities
0.00
-100.00%
0.30
-94.92%
5.90
+250.51%
-3.92
Change In Working Capital
-30.02
-235.83%
22.10
+217.20%
-18.86
-566.13%
-2.83
Change In Receivables
-7.26
-9.94%
-6.60
+45.41%
-12.09
-3.25%
-11.71
Change In Prepaid Assets
-7.85
-176.84%
10.22
+849.19%
-1.36
+63.45%
-3.73
Change In Payables And Accrued Expense
-15.17
-183.39%
18.19
+616.79%
-3.52
-127.90%
12.61
Change In Accrued Expense
-15.22
-166.82%
22.77
+2957.09%
-0.80
-112.73%
6.26
Change In Payable
0.05
+101.09%
-4.58
-68.44%
-2.72
-142.86%
6.35
Change In Account Payable
0.05
+101.09%
-4.58
-68.44%
-2.72
-142.86%
6.35
Change In Other Current Assets
0.25
-15.10%
0.30
+115.83%
-1.88
0.00
Investing Cash Flow
-418.53
-1438.57%
31.27
+124.62%
-127.00
-13541.68%
-0.93
Cash Flow From Continuing Investing Activities
-418.53
-1438.57%
31.27
+124.62%
-127.00
-13541.68%
-0.93
Net PPE Purchase And Sale
-0.37
-991.18%
-0.03
+79.88%
-0.17
+85.14%
-1.14
Purchase Of PPE
-0.37
-991.18%
-0.03
+79.88%
-0.17
+85.14%
-1.14
Capital Expenditure
-0.37
-991.18%
-0.03
+79.88%
-0.17
+85.14%
-1.14
Net Investment Purchase And Sale
-418.16
-1435.93%
31.30
+124.68%
-126.83
0.00
Purchase Of Investment
-739.76
-426.40%
-140.53
+46.95%
-264.91
0.00
Sale Of Investment
321.60
+87.16%
171.83
+24.45%
138.07
0.00
Net Business Purchase And Sale
—
—
—
0.00
Net Other Investing Changes
—
—
—
0.21
Financing Cash Flow
291.53
-20.08%
364.75
+1627.29%
21.12
+4520.79%
0.46
Cash Flow From Continuing Financing Activities
291.53
-20.08%
364.75
+1627.29%
21.12
+4520.79%
0.46
Net Issuance Payments Of Debt
0.00
+100.00%
-0.76
0.00
0.00
Issuance Of Debt
0.00
-100.00%
109.33
0.00
0.00
Repayment Of Debt
0.00
+100.00%
-110.10
0.00
—
Long Term Debt Issuance
0.00
-100.00%
109.33
0.00
0.00
Long Term Debt Payments
0.00
+100.00%
-110.10
0.00
—
Net Long Term Debt Issuance
0.00
+100.00%
-0.76
0.00
0.00
Net Common Stock Issuance
275.36
-23.43%
359.61
+1628.29%
20.81
0.00
Proceeds From Stock Option Exercised
21.36
+90.27%
11.23
+3521.61%
0.31
-56.82%
0.72
Net Other Financing Charges
-5.19
+2.37%
-5.32
—
-0.26
Changes In Cash
-320.82
-226.32%
253.96
+195.39%
-266.23
-32.44%
-201.02
Effect Of Exchange Rate Changes
-0.45
-136.51%
1.23
+99.51%
0.61
+247.13%
-0.42
Beginning Cash Position
383.22
+199.32%
128.03
-67.48%
393.64
-33.85%
595.08
End Cash Position
61.95
-83.83%
383.22
+199.32%
128.03
-67.48%
393.64
Free Cash Flow
-194.19
-36.67%
-142.09
+11.48%
-160.51
+20.41%
-201.68
Interest Paid Supplemental Data
9.46
-6.16%
10.09
+1.81%
9.91
+36.13%
7.28
Income Tax Paid Supplemental Data
1.33
+1523.17%
0.08
-97.21%
2.94
+126.56%
1.30
Amortization Of Securities
-1.80
0.00
—
—
Common Stock Issuance
275.36
-23.43%
359.61
+1628.29%
20.81
0.00
Issuance Of Capital Stock
275.36
-23.43%
359.61
+1628.29%
20.81
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
Sale Of Business
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category